Podcasts about Lennard

People pleasing, perfectionisme, moeite met grenzen aangeven en altijd het gevoel hebben verantwoordelijk te zijn. Volgens TikTok en Instagram zou het zomaar kunnen betekenen dat je last hebt van het ‘eldest daughter syndrome'. Na een luisteraarsvraag van Tessa duiken Thijs en Lennard in deze populaire term. Bestaat er echt zoiets als een oudste-dochter-syndroom, en hoeveel invloed heeft je plek binnen het gezin eigenlijk op wie je later wordt? Ze bespreken geboortevolgorde, parentificatie en de behoefte om onszelf te herkennen in psychologische labels. Want vijf herkenbare kenmerken op je For You Page kunnen een lekker duidelijke verklaring geven voor wie je bent, maar de werkelijkheid zit meestal een stuk ingewikkelder in elkaar.

Wie bepaalt eigenlijk wie je wordt: je ouders, je vrienden, of toch vooral jijzelf? Thijs en Lennard duiken in een luisteraarsvraag van de 16-jarige Arjette, die voor een profielwerkstuk onderzoekt welke invloed ouders en leeftijdsgenoten hebben op de identiteitsvorming van jongeren tussen de 12 en 18 jaar.Want ouders geven je niet alleen een opvoeding mee, maar vertellen ook het verhaal van wie je vroeger was. Leeftijdsgenoten kijken juist veel meer naar hoe je je nú gedraagt in sociale situaties. En precies tijdens de puberteit verschuift die balans: je gaat je steeds meer afzetten tegen je ouders en ontdekken wie je bent buiten het gezin.Maar zo simpel is het natuurlijk niet. Ook persoonlijkheid, cultuur, sociale media en de manier waarop je bent opgevoed spelen een rol. Dus wie heeft uiteindelijk de grootste invloed op je identiteit? En waarom blijkt die ogenschijnlijk simpele vraag eigenlijk een behoorlijk ingewikkeld onderzoeksvraagstuk?

In this episode of Behind the Genes, we explore how personalised cancer vaccines are being developed, and how genomics and AI could help make these treatments more precise.  Our host, Florence Cornish is joined by:  Dr Victoria Goss, Associate Professor of Early Diagnosis and Translational Research at Southampton Clinical Trials Unit and head of the Southampton Clinical Trials Unit Cancer Vaccine Launchpad team  Professor Lennard Lee, Associate professor at the University of Oxford, Consultant Medical Oncologist, NHS  Ali Richards, a participant who took part in a cancer vaccine clinical trial  Together they discuss how cancer vaccines train the immune system to recognise cancer, how genomic information can help identify the unique features of an individual's tumour, and how AI could help researchers analyse genomic data and accelerate the development of new cancer vaccines.   “The reason I said yes was because my treatment really was punishing. It was so many side effects to it. The cancer never made me feel sick, but the treatment made me really sick. So I said yes because I just wanted to help other people not have to go through what I went through.”    Transcript [00:00:00] Florence: What if a vaccine could help treat cancer? Hello and welcome to Behind the Genes, the podcast that brings you the stories, research, and innovations shaping the future of genomic healthcare. Today, we're going to be talking about cancer vaccines, how they're being developed with the help of AI, what role genomics has to play, and what it could mean for patients.  [00:00:23] Florence: I'm Florence Cornish, and joining me today we have Dr Victoria Goss, who leads cancer vaccine research at Southampton Clinical Trials Unit; we have Professor Lennard Lee, who is a medical oncologist and Associate Professor at the University of Oxford; and Ali Richards, who took part in the Southampton Cancer Vaccine Programme.  [00:00:45] Florence: I think before we get into cancer vaccines specifically, it might be good to start with the basics. So vaccines are something most of us have heard of and probably experienced as well, but we don't always necessarily understand how they work. So Lennard, can I come to you to explain what a vaccine actually is, how it works with our immune system, maybe at the most basic level for those who might not have a scientific background?  [00:01:19] Lennard: Thanks, Florence. What's a vaccine? Very, very simply, something that protects your body from disease. We've had a few when we were younger, like which protects you against meningitis or hepatitis or different types of infections that can affect children.  [00:01:36] Lennard: And it really does show that your immune system is really powerful. Every day, it looks around trying to work out what's there which shouldn't be there and takes care of it. And ideally, your immune system just works in the background without causing any problems. And so what a vaccine does is it really helps the body understand something that's abnormal.  [00:01:55] Lennard: And the vision here is that you can use this technology to hopefully patrol against cancer, because half the people out there will never get cancer. They are the maybe the lucky ones or maybe the ones with a good immune response. And so a vaccine is basically giving your immune system a wanted poster:  [00:02:11] Lennard: "This is what threat looks like. This is what you need to control".   [00:02:16] Florence: And I think you mentioned some great examples there. There are lots of common examples of vaccines people might have heard of. I think maybe the flu vaccine is probably a common one that people are thinking about in the wintertime. I think another one is maybe the HPV vaccine.  [00:02:29] Florence: Lennard, could you explain a bit more to our listeners about the HPV vaccine? What it is, how it works? I think people often think of it as a type of cancer vaccine, but actually it's targeting a virus. Is that right?   [00:02:41] Lennard: Yeah, that's correct. So this is now a vaccine which has been rolled out across the NHS, and it's actually worked really well to get rid of a few cancer types, which is incredible.  [00:02:51] Lennard: And why is that important? Well, cancer can be caused by many, many different things. Sometimes it's because you've done things like smoking or weight plays a role or just bad luck or the genes that you've inherited. But some cancer types are caused by viruses. And so many people nowadays are getting the HPV vaccine to stop cancer types like cervical cancer, hopefully head and neck cancer, and many of the rarer cancer types.  [00:03:21] Lennard: And so again, what you're doing here is you're taking the immune response, telling it the body shouldn't get this virus and hopefully prevent some of the bad consequence of getting this viral infection, like cancers.   [00:03:33] Florence: Thank you. That's really helpful to understand. So we've talked about how vaccines can be used to treat viruses, and I think most of us, when we hear the word ‘vaccine', we probably do associate it with something that stops us from getting ill.  [00:03:46] Florence: Victoria, could you tell us about how vaccines could be used to treat cancer?   [00:03:50] Victoria: Yeah, absolutely, and it is great to be here today. Thank you. So Lennard's already sort of spoken about preventative vaccines, and when we think about cancer vaccines, we're thinking about therapeutic vaccines. So we're thinking about training the immune system to recognise the cancer as something that needs to be dealt with because cancer is really tricky because it's our own cells that have gone wrong, if you like.  [00:04:16] Victoria: But that means it also is very good at evading those signals which tell the immune system that it needs to be cleared. So the analogy that Lennard has already given of a cancer vaccine sort of creating a wanted poster sort of builds on an analogy from one of your previous podcasts where they described the immune system as like the police almost trying to catch criminals, which are the cancer cells.  [00:04:41] Victoria: And the cancer vaccine analogy builds on that. So you've created a wanted poster which is training and giving the police more information about what those cancer cells look like. And then when we think about building on that with sort of personalised cancer vaccines, which is an incredibly exciting step when we think about the development of how cancer vaccines can be used, sort of really individualised therapy going forward, that wanted poster gets even more specific.  [00:05:07] Victoria: It's almost like giving a phone number or an address for that specific cancer type that is very specific to that patient. So the therapeutic vaccine is, is targeting the immune system. It's training our immune system to recognise the cancer as something that needs to be dealt with.   [00:05:26] Florence: It's funny you mentioned that analogy because I was just about to point listeners to that episode. If anyone wants to learn more about cancer vaccines specifically, you can check out our previous Genomics 101 podcast episode called ‘What Are Cancer Vaccines?' So Ali, I think I'd love to bring you in at this point because you have experienced this from the patient side of things.  [00:05:49] Florence: Could you tell us a little bit about your journey, your cancer diagnosis and treatment, and maybe more about the clinical trial you were part of, if you feel comfortable sharing that?   [00:05:57] Ali: Yeah, sure. Hi, Florence. It was Christmas 2015, and I felt a lump in my neck. And maybe because I'm a woman and we're always taught to treat lumps seriously, in the January I made an appointment with the GP, and she very quickly fast-tracked me through to the hospital.  [00:06:19] Ali: And January 2016, I got a diagnosis. It was a tumour on the base of my tongue at the left, and I was told it was caused by a variation of the HPV virus. So yeah, that was all a bit of a shock. I was shocked and I was scared, but I was also really angry because I look after myself. I eat well, all those things.  [00:06:45] Ali: It's just bad luck that it was a virus that my body couldn't deal with. I just, I felt guilty as well because of what I was gonna put the family through. So I had various scans and tests. I had an operation to remove my tonsils, although we soon discovered there weren't any left anyway. And they took a biopsy, which I didn't know at the time, but turned out to be important later on for the trial.  [00:07:15] Ali: Then I had to have a whole load of prep beforehand because of the impact of the treatment. So I had to have restorative dentistry, audiology tests. I had a PEG fitted, that's a feeding tube, in my stomach, and I thought, "Surely it's not going to be this bad." But that PEG, that feeding tube was a blessing in the end.  [00:07:40] Ali: And I had a mask made, and the mask fits you and basically pins you down to the radiotherapy table so you don't move when... because it's very precisely targeted at your tumour. So yeah, I went on to have five sessions of chemo, which felt quite easy. The radiotherapy was the really, really tough part. I had, uh, seven weeks of it, 35 sessions.  [00:08:08] Ali: So that was, yeah, that was a challenge.   [00:08:11] Florence: Thank you, Ali. Thank you for sharing that. I think it's always really valuable to get that patient perspective when we're talking about things like this. Lennard, I wanted to come back to you now to talk about the different types of vaccines that exist and which ones are being used specifically in the treatment of cancer.  [00:08:30] Lennard: Um, thanks, Florence. And Ali, are you 10 years now down the line since your diagnosis?   [00:08:34] Ali: Yeah, it feels good.   [00:08:37] Lennard: Congratulations.   [00:08:38] Ali: Yeah, yeah. It feels good. I really valued the follow-up checks that I had, both from my oncologist, but also I got some through the trial, and it really helped restore some confidence in myself and my body to deal with things and to be able to move on as well.  [00:08:56] Lennard: Oh, well done. That's fantastic because you telling us that story just really brings it to life about how scary this can be and also the fact that you had to go through all those sessions, thirty-five sessions and, um, and now you're 10 years down the line and still talking and giving hope-   [00:09:11] Ali: Yeah ...   [00:09:11] Lennard: that new technology still comes, so thanks, Ali.  [00:09:13] Ali: That's a pleasure.   [00:09:14] Lennard: Um, yeah, so Frances, this is what's really exciting. What types of vaccines are there? Well, first thing to say is that we're really good in this country about vaccine research. If you look around the world, what are we good at? Well, everyone knows that we developed the pandemic vaccine, and actually that technology is something that we can control.  [00:09:31] Lennard: We're world leaders at. It's quite cheap technology, and it's something that we are really good at bringing to patients. And Ali's our testament where she got on the trial, she helped test it and really pioneered new ways of research. So what types of vaccines are there? Well, I think we talked to the first bit where Victoria taught us that some of them can treat cancers and some of them can maybe prevent cancers.  [00:09:53] Lennard: And the HPV's one which is maybe be able to do both one day, which is brilliant. What would like... what else do people know about? Well, people might know that there are different types of technologies. So if we think back a few years now, back to 2020, there are some which are viral-based, and some which are mRNA based.  [00:10:12] Lennard: Both of these were new technologies which the whole population of the world came together to create and some of them are peptide-based. So there's probably three different types here. The protein ones or peptide one, which you always had, and then in the last five years, it's an incredible time to be alive, where new vaccine technology comes through, it's more effective and safer.  [00:10:32] Lennard: These are the viral ones and mRNA ones, and everyone's now pursuing all of these to try and make sure that we can maybe treat cancer in future.   [00:10:41] Florence: Can I possibly pick your brain a little bit more about the mRNA ones specifically? I think as you mentioned, lots of people might have heard of those during COVID.  [00:10:50] Florence: Could you maybe explain a little bit more about those and how they work?   [00:10:53] Lennard: Yeah. So this is going to take us all the way back to GCE biology now. If you remember - and we are Genomics England, so we, we got to work out why genomics is important, and we'll probably get to this. But remember, genes make RNA, which then makes protein.  [00:11:11] Lennard: And so if you're trying to reprogramme the immune response, you could give your body a protein, the back end of it. You can maybe give it an RNA, which is a blueprint too. And so what an mRNA vaccine is, it's a way of giving the blueprint or the instructions to the body of what to recognise, what the cancer looks like, um, um, or what the virus looks like, and target it.  [00:11:32] Lennard: If you want the analogy, well, for those people who had the pandemic vaccines, the ones which was mRNA based was, uh, the Pfizer one, and that worked really, really well. Cheap to make, easy to produce, and, uh, it's just a jab. And so people are now exploring that for cancer treatment now. Take new technology, which has only been developed five years ago, technology, which is just a blueprint, cheap to make, easy to update, and now we're targeting cancer.  [00:11:59] Lennard: Um, so that's basically what an mRNA vaccine is, giving the body the blueprint or the instruction of what a cancer looks like and trying to target that cancer.   [00:12:08] Florence: And you kind of alluded to it a little bit in your answer, but, um, it would be good to know more about where genomics comes into all of this. You know, why is it such an important part of developing vaccines?  [00:12:18] Lennard: And that's a great question, and really comes back to our second strengths, which is that we're really good at vaccine research, and yet we are also world leaders at genomic research. It's a really exciting time because, um, when Victoria and me and Ally at school, we would-- we, we learnt about that race to sequence the first human genome.  [00:12:38] Lennard: It was really exciting because for the first time, we can see every single genetic base in every human, and that used to cost billions of pounds to do that, and it would take many months or years to do that Fast-forward a few years, and then now Genomics England delivered the next success for humanity.  [00:12:57] Lennard: I think it was about 2015 to 2017 where they, they did 100,000 Genome Project, where the UK led the world in sequencing 100,000 people, including people with cancer, to try and understand what caused their cancer, what the risk factors are. And why is that relevant now? Well, it's because if you know what a cancer looks like, then you know what the abnormality is, well, then you can vaccinate against it.  [00:13:22] Lennard: So we've now gone from this amazing arc of discovery here, where when we were at school, we worked out what the human genome looks like. We can sequence it end to end and see in all its detail. Then a, an amazing organisation came out the ground called Genomic England, which shows that you can run it in the NHS.  [00:13:39] Lennard: 100,000 people could do it. And now we're making the next big jump now, which is it's not just going to give you a diagnosis, but maybe becomes a drug and a vaccine in future. And actually, probably it already has because Ali's that example, a success example of it happening.   [00:13:54] Florence: Yeah, I wanted to actually ask you about that, Ali.  [00:13:56] Florence: So just as you were saying, Lennard, it kind of... The cancer vaccine sounds quite futuristic, but as you said, it's, it's sort of already happening. So Ali, do you remember kind of how you first heard about the cancer vaccine trial?   [00:14:11] Ali: Yeah. I had a bit of an unfortunate time because after all that radio and chemo, my cancer still hadn't gone, and I had to have an operation to remove lymph nodes.  [00:14:22] Ali: But my oncologist at Poole Hospital, who's a fantastic woman, she had been involved, unknown to me, in the some of the thinking behind the trial, and particularly that she could recruit people because they were sat in her office. So she asked me if I'd like to take part, and without knowing anything, I said yes.  [00:14:49] Ali: And the reason I said yes was because my treatment really was punishing. It was so many side effects to it. The cancer never made me feel sick, but the treatment made me really sick. So I said yes because I just wanted to help other people not have to go through what I went through. I didn't really understand it, if I'm perfectly honest.  [00:15:16] Ali: I didn't really know what was going on, but then I'm not, you know, a super brain like Lennard and Victoria. I knew that I just wanted to do something to help people going forward, not having to deal with the same. So yeah, I put my hand up and there I was on the trial.   [00:15:37] Florence: So you mentioned there the, the really horrible side effects that you got from your original treatment. Did you have, um, what was your experience with side effects with the vaccine? Was it similar? Was it different?   [00:15:47] Ali: Oh, no, the, the vaccine was like a holiday compared to the treatment. Absolutely. At, at worst, in the first few treatments, you felt a bit like you had a cold, bad cold coming on, maybe slightly flu-y, but you took, you were given Ibuprofen at the same time as you had the vaccine.  [00:16:10] Ali: So no, it, the treatment with the vaccine was an absolute breeze. Which is kind of like, yes, this is what I want for people. You know, not, not the radiotherapy, not the chemo. So yeah, it was, it was really very easy by comparison.   [00:16:29] Florence: Oh, I'm so glad to hear that that was your experience. I'm just curious now also, was there anything that surprised you about the trial?  [00:16:35] Florence: You said there that you didn't really, like, have an understanding of cancer vaccines. You, you agreed to it straight away. Was there anything that maybe, like, you weren't expecting or surprised you?   [00:16:45] Ali: I think it surprised me that it was really quite easy.   [00:16:48] Florence: Yeah.   [00:16:49] Ali: Uh, I was delighted to have the team I had looking after me because they were fantastic. It all felt very simple.  [00:16:59] Ali: And how nice that was. You know, if I could've had that instead of all my previous treatments, um, it would've, it would've made everyone's life so much easier. And I guess, I don't know about the cost of drugs, but I guess the cost to the NHS would've been less because I wasn't in and out of hospital, I wasn't having to have all these extra things done, and all this extra support like dieticians and so on because I had to have my feed tube replaced.  [00:17:35] Ali: So all of that is impacts on the NHS, whereas this was very simple.   [00:17:40] Florence: I wanted to come to you now, Victoria, and ask you about the outcomes of this trial that Ali took part in or other trials like it, and whether we know yet what the broader implications of, of these advances might be.   [00:17:55] Victoria: So I think what we need to think about when we're thinking about developing these treatments and sort of evaluating the treatments at each stage is that it goes through a very clear pathway of progression, and Ali was involved in one of the, the earliest stages of that progression.  [00:18:09] Victoria: And it's, it's always amazing to me to hear your story, Ali, and to know that patients are willing to take part in the research and that's what allows us to develop these treatments. So the trial that Ali was part of has now gone on to develop into a, a larger scale study which will be evaluated again.  [00:18:27] Victoria: And that all starts to form the evidence for how these treatments can be shown to be effective, and also how they can show... Also, you know, Ali's already touched on there about the cost implications, so how we can show that that can be beneficial as well. And then we can start to think about how they can be taken up and become part of routine standard of care for patients like Ali, as she was describing.  [00:18:50] Victoria: And all of that evidence comes together, which then gets evaluated and then it, and then it moves forward through that progression. But it's-- we have very clear, um, you know, a, a route that each new, new treatment has to go through, um, to be able to, to become part of standard of care.   [00:19:07] Florence: And Victoria, you also play a key role in the Cancer Vaccine Launchpad.  [00:19:12] Florence: For any listeners who might not be familiar with the Cancer Vaccine Launchpad, could you maybe tell us a little bit more about it?   [00:19:18] Victoria: Absolutely. So in its simplest terms, the Cancer Vaccine Launchpad is designed to help find patients who might be eligible to take part in trials like the one that Ali was part of.  [00:19:30] Victoria: It's an incredible project. Cancer Vaccine Launchpad is quite long, so we tend to abbreviate it to the CVLP, which I'll do from now on, if that's okay. The CVLP to me really demonstrates the power of collaboration because it's brought together so many different teams that have been necessary to make sure that, that what we're trying to achieve, so finding as many patients as possible for these trials, is possible.  [00:19:52] Victoria: We deliver this project on behalf of NHS England. I know that Lennard was involved right from the start as well. The reason that we need the CVLP is because one of the biggest challenges in research of these new treatments is finding the patients who might be eligible. So one of the reasons for that is because when we are running the trials to test these new treatments, there's a lot of different infrastructure that's needed to support the delivery of those trials.  [00:20:19] Victoria: So you need special pharmacy services, special research nurses. All of that has to come together to be able to deliver trials of new treatments. And actually, that means that actually those studies can often only take part in a small number of hospitals. So historically, you only had the opportunity to take part in those trials if you lived near one of those hospitals, which is, you know, like Ali did.  [00:20:42] Victoria: So what the CVLP is, what, what it has done, it has created a formalised network which enables referrals to happen from ... we're opening 83 hospitals now across England. We've just expanded out to the devolved nations as well, which is a really exciting development, and it creates that, that network which allows patients who might live further away from a hospital delivering one of those vaccine or immunology trials to be able to be referred in to see if they might be eligible.  [00:21:09] Victoria: So essentially, it's a bit like creating a big funnel. So you're finding all of the potentially eligible people that could take part in that trial, and you're funnelling them into the trial site to find those patients who are eligible.   [00:21:22] Florence: And what impact do you hope that this could have for the NHS and also for, like, individual patients as well?  [00:21:29] Victoria: So we've seen such positive results from the CVLP so far. The first study that we worked with was for a colorectal cancer vaccine trial. Before the CVLP started working with this trial, only 17% of the eligible patient population in England had the opportunity to take part because they lived near one of those hospitals delivering the trial.  [00:21:52] Victoria: After the CVLP started working with it, we had increased that to over 60% of the eligible patient population. So you could really see how it has expanded out access, and that's just a fantastic opportunity to be able to bring, to bring patients. We also were able to show that the UK was screening, so looking for patients at three times the global average.  [00:22:14] Victoria: So we really were able to see how the CVLP is supporting and accelerating recruitment to those trials I think the key thing for me has been the patient enthusiasm that we have seen though. So when we open up to a new trial where, that the CVRP is working with, we are always inundated with people who contact us to find out how they can be part of this network because they want the opportunity to take part.  [00:22:40] Victoria: We know that some patients have travelled for two hours to a trial site to find out if they could be eligible because actually they want the opportunity. So the CVRP has really sort of enabled that patient choice, which is a fantastic thing to be able to do. But it also builds on what Lennard was talking about earlier, which is the UK is really good at this research and actually what the CVRP is then doing is showing how we can really support recruitment to these trials to accelerate these trials and that only brings more trials to the UK which again creates more opportunities for patients which is exactly what we're trying to do.  [00:23:14] Victoria: We're trying to create more and more opportunities for patients to take part in these studies if they want to.   [00:23:20] Florence: Yeah. That's really incredible. Thank you for sharing that with us. I wanted to ask you a question now, Ali, because I think when we were talking about trials and projects like this, as Victoria said, we often think about kind of the high level impact, but also it's an opportunity to create connections as well between patients and families and, and I know that you, you had a patient's family reach out to you about advice as to-- about whether they should take part in a trial. Is that right?   [00:23:47] Ali: Yeah. I think it was the wife of a guy up in Liverpool who had throat cancer, and, um, she must have done some really good research on the internet. I'd done various bits of publicity both for Southampton Uni and cancer research around the trial. So she obviously found me and then stalked me on Facebook , which was absolutely fine.  [00:24:13] Ali: I didn't have a problem. So her husband was down to go on the trial, which is the next stage that Victoria had spoken about, and she just wanted to know, would I recommend it, would-- what was it like, that kind of thing. So I said to her, "I would absolutely recommend it, of course," and told her what my experience was.  [00:24:35] Ali: I couldn't guarantee his would be the same, of course, because things might have moved on. But it was a really, it was a kind of a nice feeling that I could say to her, "Get him to have it done because it's got to be the best outcome." I think his stage was much further on than me. So yeah, it had to be the way as far as I could see for him. And as far as I know, he went on the trial. Which is great.   [00:25:05] Florence: How, how did it feel to kind of make that human connection, maybe not something you were expecting to come out of a trial?   [00:25:13] Ali: No, it was really, it was really nice. I am a bit of a, a fangirl for, for Lennard and Victoria and all the team at Southampton.  [00:25:22] Ali: If anybody asks me about vaccines and cancer vaccines, I'm like, "Oh, yes." And you-- So yeah, I'm, I'm a bit of an evangelist. So to, to have somebody real-   [00:25:33] Florence: Mm ...   [00:25:34] Ali: ask me about that was great feeling.   [00:25:37] Florence: I think that's a, a really great example of how research can have impact far beyond, uh, one individual. And I think another great example of this is also artificial intelligence or AI as a potentially transformative force in, in healthcare.  [00:25:54] Florence: Lennard, when we come onto this topic, I wanted to hand over to you because I know that you've recently received funding for a project exploring AI, and how it could support cancer vaccine development in particular. Could you tell us a bit more about this project?   [00:26:08] Lennard: Thanks very much, Florence. And I also want to add, I feel very proud about what Ali did just there, where she's able to bring through opportunity for other people, too, which is amazing.  [00:26:19] Lennard: The NHS is there to not just do the technology of today, but also be one of the best healthcare systems in the world to bring through new technologies. And it's just really exciting about people wanting to help the NHS, advocating for new technologies to be tested, and actually that's what Genomics England i there to do, make sure the NHS gets new technology in there so that patients will get new treatments.  [00:26:41] Lennard: I just wanna just reflect what Victoria noted In the NHS, in their Cancer Vaccine Launchpad, patients are getting in at three times the rate of other countries.   [00:26:51] Ali: Mm-hmm.   [00:26:52] Lennard: That's really special. And also she's increased coverage to, uh, did you say 60% of population? That's 42 million people have potential access to this.  [00:27:01] Lennard: So that is huge, and I think it's really a passion project for so many people out there, PICT trials units, the research nurses and doctors, and also patients who make this all happen. So it is quite impressive. It is very impressive. Oh, yes, and AI. I probably should cover that too. Just beyond what's special about the NHS and Genomics England.  [00:27:22] Lennard: Well, AI I think is changing everything. I went to a garden party, and actually everyone's talking about how they're using AI to make their lives simpler, make them do things that they've never been able to do before, get the information instantaneously there. And I think that there's technologies which come through every so often in our lifetimes, which changes how we think, how we communicate, and actually makes us better in many ways.  [00:27:47] Lennard: And so the great opportunity here is what happens if we take that third strength now? So we've already said we're really good at vaccine research in the UK. The UK invented vaccines. We also are world leaders at genomics. We did the 100,000 Genome Project. What happens if we use this new technology now?  [00:28:06] Lennard: And what's a problem that we can solve? Well, let's say we did a whole genome sequence on someone, which is what Genomics England does every day for the NHS. Well, that creates a lot of data. Um, I tried to do the calculations before we went online. It's about 100,000 photos. You know, when you take on your phone, that's a lot of data.  [00:28:25] Florence: Wow. Yeah.   [00:28:26] Lennard: And that's a miracle what's happening in the NHS and Genomic England, and we need to make a cancer vaccine out of that. And so you need to process that. So that's time-consuming. It could be automated. And so what AI could do now in future is that we could use the supercomputer we built in the UK.  [00:28:43] Lennard: In fact, we are doing this already. We've built supercomputers in the UK, and we're going well beyond other tools out there and designing cancer vaccines. And the AI scientists which can do that can do it at weekends, at nights, and help design the drugs. And so what it does is it heralds a future where every patient can contribute into a model that's created in the UK, stored safely in our supercomputers.  [00:29:07] Lennard: It can now be made into drugs, and the UK will start to make things again, which will hopefully change cancer care across the world. We can deliver that legacy whereby our three strongest strengths come together - vaccines, AI, and genomics. It then super powers the NHS and everything that Victoria's done in the Cancer Vaccine Launchpad, so many millions of people around the world can get access to trials.  [00:29:31] Lennard: And people like Ali can also help hold up the NHS even further. So people once again look back to us and say, "If you want to get things done, come to the NHS because it provides world-class care for patients." And so that's a big initiative now. Use AI to make better drugs, safer drugs, more effective, more precise in the UK. And it's only possible because of everything that we've built here with our funders, ARIA, MRC, Cancer Research UK, people raising, raising money through cake bake sales to make this happen.  [00:30:02] Lennard: So it's very exciting.   [00:30:04] Florence: Yeah. I think AI can be a topic that people often have very strong opinions about. When it comes to AI in, in your line of work, are there any misconceptions you think people might have, or are there any benefits to using it that maybe people might not be aware of?   [00:30:21] Lennard: Oh, that's a tricky question, isn't it? I think you're right. Any tool that comes through can be used for good things and, and things that people will question because maybe we don't want to cross those boundaries. And yet I think what we're doing here is really special because we want to - as long as your heart's in the right place - we want to give more people like Ali hope so that she knows that one day the drugs in the NHS will be much safer so you don't get all those side effects, much more effective, much more precise.  [00:30:52] Lennard: And on top of that, people like Victoria will be able to bring even more trials in the UK which will change lives and change practices around the world through an amazing working launchpad. So I think that's the right use of AI, make people's lives better. I think there are other uses of AI which I probably scratch my head and say, "Well, should we be doing that?"  [00:31:10] Lennard: And that's what I think it's really special that we do think about these and talk about these things here, and then bring the public with us because I know that people reach out, and Ali's been reached out in the past before, and I think we need to have this discussion here. Is AI right to develop cancer drugs using capabilities from Genomic England to go through the NHS Cancer Vaccine Launchpad?  [00:31:31] Lennard: I say cautiously, yes, and we should do more of this. And I think the most important thing is there's a lot of people starting to use AI for benefit, and you know my views, Ali, and I don't know if they're right. Um, I'll be a bit cautious, but I do want to ask you, Ali, is this the right use of AI? Should this be what we develop?  [00:31:50] Lennard: I don't know what you're going to say.   [00:31:52] Ali: For me, I think it is. I do think AI is a bit if you put rubbish in, you get rubbish out. But if you- If you ask the right questions, if you give it data analysis and experts like you have set up the protocol in the first place and it makes everything faster and reliable, then it's got to be the right thing.  [00:32:16] Ali: It gets used and abused for things, that isn't what AI should be doing, in my opinion. It should be used to do-- to help us, to supplement the work that we're doing, uh, and make it even faster than you're already making it.  [00:32:38] Florence: Well, we've covered so much today from how vaccines work to the role of genomics, NHS trials, and of course, what all of this could lead to. So before we wrap up, I have two final questions for each of you. What do you think is the most important thing for listeners to understand and take away from personalised cancer vaccines?  [00:33:01] Florence: And what are your hopes for the future? I think we'll start with you, Victoria, if that's all right.   [00:33:08] Victoria: Yeah, absolutely. It's been a great conversation. Uh, there's so much to think about. I think when I think about what I'd like listeners to take away, I think it's that cancer vaccines, and particularly personalised cancer vaccines, really support and represent this paradigm shift that we're seeing towards a much more personalised, uh, treatment pathway.  [00:33:27] Victoria: You know, like we've described, generating a cancer vaccine that has come from the patient's tumour, so the, the, the vaccine is, is designed to recognise mutations that are specific to that patient. It is such an incredible thing to be sort of witnessing and to see how that's developing through into sort of really changing patient care, and that's, you know, we've spoken about this so much, but that's been due to such incredible collaboration across scientific disciplines, across the NHS, pathologists.  [00:33:58] Victoria: Everyone has come together to make all of this possible, and that's, that's an amazing thing to be a part of. In terms of my hopes for the future, well, I would like the Cancer Vaccine Launchpad to be open in every hospital across the UK to really sort of underpin that acceleration and to provide that opportunity for patients.  [00:34:17] Victoria: You know, I'd just like to give a, a final shout-out to everybody who has been part of the Cancer Vaccine Launchpad from its very start, who's enabled this to happen and, you know, it's just been fantastic to see how this has, you know, supported patient choice for trials. And I guess if there's one tiny other thing, perhaps we could see how this, you know, this, what we've put together could be applied to other disease areas as well.  [00:34:39] Victoria: But yeah, that, that would be my hope for the future, is it's open everywhere one day.   [00:34:43] Florence: And Ali, I'll come over to you next.   [00:34:45] Ali: I think what I'd say to any patient that was asked to go on a trial is, is just go for it.  [00:35:02] Ali: And you know, Victoria, Lennard, all the rest of the team, you know, you are not doing jobs. You're leaving a legacy in my view. That's such an important thing. So yeah, if you're offered a trial, get on it. And my hope for the future is that everybody can have kinder, gentler treatments. The radiologists and chemo nurses I came across were lovely, lovely people.  [00:35:31] Ali: But yes, I'd like to see them out of work and doing other things within the NHS because they don't need to do that work anymore. That, that's my dream.   [00:35:40] Florence: Mm. And Lennard, any, any final thoughts?   [00:35:44] Lennard: Thanks, Ali. I mean, your words gave me goosebumps about the amazing stuff that the whole community's doing for cancer vaccines, AI and genomic research.  [00:35:51] Lennard: It's so powerful. Um, okay. What's the final thing? I think it's hope. Look, the country's in a new place now. You've got brilliant scientists running clinical trials, like the Cancer Vaccine Launchpad, which is reaching out to every single hospital. You've got patients who are building up the NHS again to deliver future care, and scientists using AI and genomics to make cancer vaccines.  [00:36:11] Lennard: That is a good reason to be hopeful. When lots of things are going in other places of the world, great things are happening in the UK.   [00:36:20] Florence: This has been such a brilliant conversation.  [00:36:25] Florence: A huge, huge thank you to our guests today, Dr. Victoria Goss, Professor Lennard Lee, and Ali Richards, for joining me in our brilliant discussion about cancer vaccines.   [00:36:50] Victoria: Thank you so much for having me.  [00:36:55] Ali: Thank you, as always. I've learnt a lot.   [00:37:00] Lennard: Thank you very much, Florence, too, from me.   [00:37:10] Florence: If listeners have enjoyed this episode and you'd like to hear more, please subscribe to Behind the Genes on your favourite podcast app.  [00:37:16] Florence: I've been your host, Florence Cornish, and Behind the Genes is produced by Deanna Barac, Sharon Jones, Sophie McLachlan, and Patrick Wallace at Bespoken Media. Thank you for listening.   

Word je echt gelukkiger van een huisdier, of voelt dat vooral zo omdat kittens nu eenmaal heel moeilijk te haten zijn? Na de komst van Mickey en Bobby, twee extreem knuffelbare asielkittens, duiken Thijs en Lennard in de vraag of katten, honden, goudvissen of eventueel een wandelende tak goed zijn voor je mentale gezondheid. Want ja, zo'n beestje kan zorgen voor gezelschap, knuffels en een iets minder harde landing na sociale afwijzing, maar nieuw onderzoek zet ook vraagtekens bij het idee dat huisdieren automatisch zorgen voor minder eenzaamheid of meer levensgeluk.

Heb je echt een serotoninetekort als je depressief bent, of is dat verhaal misschien iets te makkelijk geworden? Omdat Thijs op vakantie is, duikt Lennard solo in de serotoninetheorie van depressie, SSRI's, antidepressiva en een grote umbrella review die twijfelt aan het idee dat depressie simpelweg ontstaat door een tekort aan één stofje in je brein. Want ja, antidepressiva kunnen mensen helpen en als het voor jou werkt moet je vooral niet op eigen houtje stoppen, maar het is wel de vraag of ze iets “fixen” of vooral je mentale toestand veranderen. Kortom: een gezellig rondje langs depressie, hersenstofjes, pillen en de vraag of we moeilijke dingen soms iets te graag simpel maken.

„Wir werden ein Logistikunternehmen sein müssen – die Logistik wird langfristig den Erfolg dieser Firma definieren.“ In dieser Folge von Behind the C spricht Franz Kubbillum mit Lennard Neubauer, dem Managing Director von Lieferando Deutschland. Die Plattform verbindet rund 17 Millionen aktive Kundinnen und Kunden mit etwa 50.000 Restaurants, Supermärkten, Apotheken und weiteren Partnern. Lennard erklärt, warum sich Lieferando vom reinen Vermittler für Essensbestellungen zunehmend zu einem technologiegetriebenen Logistikunternehmen entwickelt und weshalb die eigene Auslieferung für das künftige Wachstum entscheidend ist. Dabei richtet er den Blick auch auf neue Produktkategorien und die Frage, wie Künstliche Intelligenz Prozesse verbessern und Menschen wirksamer zusammenarbeiten lassen kann. Der gebürtige Hamburger zog bereits mit 16 Jahren nach England, um Fußball zu spielen. Nach seinem Studium in Liverpool führten ihn Stationen im Commodity Trading, in der Beratung und im Private-Equity-Umfeld schließlich zu Just Eat Takeaway, wo er 2021 im Bereich Corporate Strategy und M&A begann. Seit Juli 2024 verantwortet er das Deutschlandgeschäft von Lieferando. Im Gespräch berichtet Lennard offen, warum Fokus, realistische Erwartungen und die Bereitschaft, das eigene Ego zurückzustellen, zu seinen wichtigsten Führungslearnings gehören. Ausgleich findet er beim Sport und Schlagzeugspielen, während er sich im Arbeitsalltag bewusst mit Stift und Papier organisiert. Drei Fragen, die in dieser Folge besprochen werden: - Wie entwickelt sich Lieferando vom klassischen Essensmarktplatz zur On-Demand-Logistikplattform? - Warum sind Fokus, Geduld und ein ehrlicher Blick auf die eigenen Fehler für erfolgreiche Veränderungen entscheidend? - Wie schafft eine Geschäftsführung ein Umfeld, in dem talentierte Menschen Verantwortung übernehmen und ihr Potenzial entfalten können? Themen: - C-level - Logistik - Adaptability ----- Über Atreus – A Heidrick & Struggles Company Atreus garantiert die perfekte Interim-Ressource (m/w/d) für Missionen, die nur eine einzige Option erlauben: nachhaltigen Erfolg! Unser globales Netzwerk aus erfahrenen Managern auf Zeit zählt weltweit zu den besten. In engem Schulterschluss mit den Atreus Direktoren setzen unsere Interim Manager vor Ort Kräfte frei, die Ihr Unternehmen zukunftssicher auf das nächste Level katapultieren. ▶️ Besuchen Sie unsere Website: https://www.atreus.de/ ▶️ Interim Management: https://www.atreus.de/kompetenzen/service/interim-management/ ▶️ Für Interim Manager: https://www.atreus.de/interim-manager/ ▶️ LinkedIn-Profil von Lennard Neubauer: https://www.linkedin.com/in/lennardneubauer/ ▶️ Profil von Franz Kubbillum: https://www.atreus.de/team/franz-kubbillum/

Waarom beginnen we een goed punt vaak met “misschien is dit een domme opmerking” of “ik kan het helemaal mishebben, maar…”? In deze aflevering duiken Thijs en Lennard in indektaal: de kleine zinnetjes en woorden waarmee je jezelf alvast indekt voordat je überhaupt iets hebt gezegd. Ze bespreken waarom vooral onzekerheid, bescheidenheid en de angst om arrogant over te komen ervoor kunnen zorgen dat je jezelf kleiner maakt in gesprekken, vergaderingen of therapie. Want hoewel het vriendelijk of voorzichtig lijkt, kan indektaal je punt juist minder sterk maken en ervoor zorgen dat mensen je minder serieus nemen.

"Wie leben geht" ist der erste Roman von Alex Dürer. Darin geht es um Lennard und seine Zweifel, ob er das Leben lebt, das er sollte. Er vergleicht sich mit anderen. Bei ihnen läuft scheinbar immer alles, oder? Lennard hingegen steckt fest.**********Weitere BeiträgeLiteratur: "Xerox" von Fien VeldmanLiteratur: "Das Schwarz an den Händen meines Vaters" von Lena SchätteLiteratur: "Das gute Benehmen" von Molly Keane**********Den Artikel zum Stück findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .

Waarom vinden we psychedelica spannend, maar kijken we nauwelijks op van een vrijgezellenfeest dat uitloopt op de zoveelste kroegentocht? Naar aanleiding van een opmerkelijke ervaring op een bachelorparty duiken Thijs en Lennard in de normalisering van alcohol, de angst rondom psychedelica en het belang van keuze, vertrouwen en setting. Want hoewel paddo's en LSD zeker geen middelen zijn die je “even voor de grap” doet, zegt onze nonchalance over alcohol misschien minstens zoveel over hoe vreemd onze ideeën over drugs eigenlijk zijn.

Die erste Woche in Wimbledon hat Erkenntnisse geliefert, die bisher teilweise verborgen geblieben sind. So ist Jan-Lennard Struff also doch ein Rasengott. Henrike und Daniel haben das eigentlich schon immer gewusst. AuchAlexander Zverev macht das Grün plötzlich nichts mehr aus und bei den Frauen deutet sich eine ganz besondere Siegerin an. Nur weiß die das sebst noch nicht.

Die erste Woche in Wimbledon hat Erkenntnisse geliefert, die bisher teilweise verborgen geblieben sind. So ist Jan-Lennard Struff also doch ein Rasengott. Henrike und Daniel haben das eigentlich schon immer gewusst. AuchAlexander Zverev macht das Grün plötzlich nichts mehr aus und bei den Frauen deutet sich eine ganz besondere Siegerin an. Nur weiß die das sebst noch nicht. Dieser Podcast wird vermarktet von der Podcastbude.www.podcastbu.de - Full-Service-Podcast-Agentur - Konzeption, Produktion, Vermarktung, Distribution und Hosting.Du möchtest deinen Podcast auch kostenlos hosten und damit Geld verdienen?Dann schaue auf www.kostenlos-hosten.de und informiere dich.Dort erhältst du alle Informationen zu unseren kostenlosen Podcast-Hosting-Angeboten. kostenlos-hosten.de ist ein Produkt der Podcastbude.

Wat gebeurt er met je brein als je urenlang TikToks kijkt, je sociale leven steeds digitaler wordt en zelfs AI straks een soort vriend voor je kan zijn? Aan de hand van een talk van Jonathan Haidt duiken Thijs en Lennard in brainrot, schermtijd, social media en de vraag wat al die technologie doet met onze aandacht, mentale gezondheid en relaties. Want hoe handig smartphones, schermen en AI ook kunnen zijn, ze nemen ook iets over wat kinderen en jongeren juist nodig hebben: echt contact, verveling, concentratie en tijd in de fysieke wereld. Dus moeten we technologie blijven omarmen, of is het tijd om wat technosceptischer te worden?

Von Iserlohn nach Weißwasser, in die Champions Hockey League, weiter nach Berlin und am Ende stemmt er den Pokal: Basti redet mit Lennard Nieleck über seine vergangene Saison, seine Zeit bei den Eisbären und seine neuen Aufgaben in der kommenden Spielzeit

Waarom ben je helemaal jezelf als je alleen bent, maar raak je jezelf kwijt zodra er een potentiële partner in beeld komt? Je hebt je leven op orde, weet wie je bent en voelt je gelukkig, totdat je iemand ontmoet die je écht leuk vindt... Aan de hand van een luisteraarsvraag duiken Thijs en Lennard in hechting, verliefdheid en de neiging om jezelf te verliezen in de behoefte aan liefde, aandacht en bevestiging. Want hoe leuk liefde ook is, het kan ook onzekerheid, hechtingsproblemen, gepieker en pleasing-tendencies naar boven halen.

Aflevering 114 van 'Mag ik bij je aankloppen?' In een klein half uurtje leer je deze aflevering Lennard Finke kennen. We stellen hem kort aan je voor en luisteren naar zijn persoonlijke verhaal. Tot slot gaan we er achter komen welk lied de nieuwe inzending is voor de lijst der lijsten 'Liedje erin, Liedje eruit!'. Veel plezier en laat vooral je reactie achter.

Is eenzaamheid dodelijk? Waarom kan een volle kamer soms leger aanvoelen dan stilte? En hoe vind je als volwassene nog iemand die je je beste vriend durft te noemen? Psycholoog, schrijver en podcasthost Lennard Toma beweegt zich al jaren in dat spanningsveld tussen eenzaamheid en verbinding. Als auteur van Survivalgids voor de eenzaamste eeuw, maker van de podcast Normale Mensen Bestaan Niet en oprichter van zijn praktijk Remissio, legt hij haarfijn bloot waarom eenzaamheid geen randfenomeen is, maar iets wat we allemaal meemaken. Bijna 40% van de mensen voelt zich eenzaam, en vaak juist door onze hyper-individualistische samenleving. Lennard laat zien dat boosheid geen vijand is, maar een brug. Hij spreekt over emoties die mogen bestaan, over patronen die we ontwikkelen om afwijzing te vermijden en die ons juist uit elkaar drijven. Over onze drang om ons altijd “goed” te voelen en hoe die ons soms afsluit van echte verbinding. En over een onderwerp waar we zelden bij stilstaan: de noodzakelijke kunst van afscheid nemen van vriendschappen die niet meer passen. Meer info over Lennard Toma vind je hier.  Met veel dank aan onze partners: Deze podcast wordt mede mogelijk gemaakt door Koffie Kàn, voor als jij ook koffie nodig hebt om alle ballen in de lucht te houden. Klaar om jouw eigen stem te laten horen? Wij helpen experts zoals jij groeien via podcasting. Ontdek hoe bij 50 Koffies Producties.  Gekleed door Xandres, want stijl hoort er gewoon bij. Prachtige juwelen door Maudart voor die extra sparkle. Jouw mentale welzijn als ondernemer doet ertoe. Doe gratis een beroep op hulp via Acerta, onze trotse partner van het derde seizoen. Hier vind je meer info over hun welzijnsaanbod. Ga via de tijdcodes hieronder naar een thema van deze aflevering: (00:00:00) Introductie van de aflevering. (00:02:11) Hoe maak je nieuwe vrienden als volwassene? (00:03:44) Introductie van Lennard: psycholoog, auteur en podcastmaker. (00:05:24) Lennard vertelt over zijn boek ‘Survivalgids voor de eenzaamste eeuw'. (00:07:51) Wat is het verschil tussen alleen zijn en je eenzaam voelen? (00:10:18) Opmerkelijke cijfers over eenzaamheid in Nederland en België. (00:12:49) Hoe zijn we het gevoel van gemeenschap kwijtgeraakt? (00:17:05) Hoe zit het met eenzaamheid in andere landen? (00:19:41) Waarom voel je je soms eenzaam terwijl je omringd bent door mensen? (00:23:12) Hoe uit je je grenzen op een gezonde manier? (00:26:13) Hoe kun je de woede van anderen incasseren en een relatie na conflict herstellen? (00:31:39) Hoe ouders omgaan met emoties, en wat dat doet met kinderen? (00:42:41) De gevolgen van onze prestatiecultuur en zelfkritiek. (00:46:11) De lastige balans: hoe wil je uniek zijn en tegelijk bij een groep horen? (00:48:19) Waarom millennials de sandwichgeneratie zijn. (00:50:29) Waarom is mildheid voor jezelf zo belangrijk? (00:54:00) De maatschappelijke drang naar geluk en waarom je best negatieve emoties toelaat. (00:56:19) Hoe herken je je onbewuste emoties en gedragspatronen?  (01:00:33) Het verschil tussen familie en vrienden, en wat dat betekent voor eenzaamheid. (01:07:27) Vragen over het loslaten en onderhouden van vriendschappen. (01:11:00) Wat zou Lennard doen als hij ‘minister van eenzaamheid' zou zijn? (01:15:02) Einde van de aflevering. 

Der Mitgründer und CEO des Berliner Start-ups spricht über KI-Agenten, vermeintlich dystopische Szenarien – und die Frage, warum seine Firma so leise auftritt.

Na een experiment van Nijmeegse onderzoekers kopte de Volkskrant dat er een soort “uitknop” voor angst zou bestaan. Thijs en Lennard duiken in het onderzoek naar de amygdala, het deel van het brein dat betrokken is bij dreiging en angstreacties, en bespreken wat aangeleerde angst, exposuretherapie en hypergeluid met ons brein doen. Want wat gebeurt er eigenlijk als je het angstcentrum van je brein verstoort? En is angst iets wat je ooit écht uit kunt zetten, of hebben we het juist nodig om niet telkens dezelfde fouten te maken?

Bei Klimamodellen werden die allerextremsten Zukunftsszenarien nicht mehr berücksichtigt – sie gelten als unwahrscheinlich. Die Leugner freuen sich – grundlos. Denn auch in den vorsichtigeren Prognosen kommt es zu einer starken Erwärmung.**********In dieser Folge mit: Moderation: Diane Hielscher**********Weiterführende Quellen zu dieser Folge:Van Vuuren, D. P., O'Neill, B. C., Tebaldi, C., Sanderson, B. M., Chini, L. P., Friedlingstein, P., Hasegawa, T., Riahi, K., Govindasamy, B., Bauer, N., Eyring, V., Fall, C. M. N., Frieler, K., Gidden, M. J., Gohar, L. K., Högner, A., Jones, A. D., Kikstra, J., King, A., Knutti, R., Kriegler, E., Lawrence, P., Lennard, C., Lowe, J., Mathison, C., Mehmood, S., Nicholls, Z., Prado, L. F., Zhang, Q., Rose, S. K., Ruane, A. C., Sandstad, M., Schleussner, C.-F., Seferian, R., Sillmann, J., Smith, C., Sörensson, A. A., Panickal, S., Tachiiri, K., Vaughan, N., Vishwanathan, S. S., Yokohata, T., Zecchetto, M., and Ziehn, T. (2026): The Scenario Model Intercomparison Project for CMIP7 (ScenarioMIP-CMIP7), Geosci. Model Dev., 19, 2627–2656.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .

Thijs heeft een nieuw boek aangekondigd: 'In ons schuilt ook een Trump', en Lennard schrikt een beetje van de titel... én van de cover! Samen duiken ze in het werk van Carl Jung, de schaduwkant van de mens en de vraag waarom figuren als Trump zoveel losmaken in de wereld.Volgens Jung projecteren we het kwaad graag op anderen, terwijl we die duistere kanten zelf ook bezitten. Lennard en Thijs praten over projectie, collectieve psychologie, massapsychologie en waarom Jung juist nu misschien relevanter is dan ooit.

Medicinale wiet wordt vaak gezien als de oplossing voor stress, angst of slaapproblemen. Maar klopt dat wel? Lennard duikt met Thijs in een grote meta-analyse en de conclusie is minder rooskleurig dan je denkt... Voor fysieke klachten zoals pijn of epilepsie lijkt cannabis soms te helpen. Maar bij mentale problematiek, zoals depressie of PTSS, is het effect zwak of zelfs negatief, met risico's op verslaving en psychotische klachten.Kortom: wat voelt als ontspanning, kan ook iets anders zijn. Tijd om iets kritischer te kijken naar dat “medicinale” verhaal.

Je verjaardag: leuk voor de één, ongemakkelijk voor de ander. Thijs kijkt er elk jaar tegenop. Aandacht krijgen zonder “iets gepresteerd te hebben”, de druk om er iets van te maken en dat knagende besef dat de tijd gewoon doorgaat… In deze (eerder opgenomen) aflevering, toen hij nog “morgen” jarig was, duikt hij met Lennard in de psychologie achter de "birthday blues”, en waarom sommige mensen juist rond hun verjaardag meer stress of somberheid ervaren. Goed nieuws: je bent niet de enige! En een beetje humor helpt vaak meer dan je denkt.

Während in der Ukraine der Krieg andauert, entsteht im Hintergrund eine andere Art von Bilanz. Der CO2-Experte Lennard de Klerk berechnet die unsichtbaren Schäden des Krieges: Emissionen, zerstörte Infrastruktur, verbrannte Wälder. Im Gespräch erklärt er, wie sich Umweltschäden beziffern lassen - und warum sie künftig Teil von Reparationen sein könnten.

Altijd moe van werk, of juist kapot van verveling: wat is nou het verschil tussen een burn-out en een bore-out? Thijs en Lennard leggen uit waarom “burn-out” eigenlijk een rommelige term is, hoe verveling óók stress kan geven en waarom bullshitbanen je net zo goed kunnen slopen als overwerken. Inclusief praktische tips: wanneer trek je aan de bel en wat kun je zelf doen als je werk je leeg trekt of juist totaal niet prikkelt?

Today's guest is Donna Lennard, the founder of il Buco and one of the defining figures of downtown New York dining. Since opening il Buco in 1994, Donna has slowly and thoughtfully built a hospitality group founded on passion, great ingredients, and welcoming vibes. The business includes il Buco Alimentari in NYC, il Buco outposts in Amagansett and Ibiza, il Buco Vita shops, and a line of il Buco pantry staples.  She joins host Kerry Diamond to share the story of how il Buco came to be, and the personal journey that led her from a career in film to hospitality. She reflects on hiring and leadership, why doing what you love is her guiding principle, the dish that's never leaving the menu (hello, kale salad), and the food world legend she'd want with her on a desert island. This interview was recorded at Newsstand Studios at Rockefeller Center.  Cherry Bombe on SubstackOur new Mom's the Bombe issue Visit cherrybombe.com for subscriptions, tickets to upcoming events, and more. More on Donna: Instagram, il Buco, il Buco Vita More on Kerry: Instagram, “So You Want To Open A Restaurant” Substack series

Links logisch en rechts creatief, maar klopt dat eigenlijk wel? Thijs en Lennard duiken in split-brain experimenten, hersenschade en bizarre cases waarin mensen gewoon functioneren met een halve hersenpan. Van patiënten die niet weten waarom ze iets doen tot het idee dat je brein achteraf verhalen verzint over je gedrag. Hoe één is je bewustzijn eigenlijk… en snappen we überhaupt iets van dat ding in ons hoofd?

Lennard traut sich zu, unter Wasser zu sein. Weil er die spannende Welt der Fische und Krabben und Quallen ganz genau beobachten will, macht er den Tauchschein. Mit Tim.

In der zweiten Folge unserer USA-Tour ist Jan-Lennard Struff zu Gast – einer der beständigsten deutschen Tennisprofis der vergangenen Dekade.Wir treffen ihn entspannt, aber fokussiert: kurz vor seiner ersten Partie in Indian Wells, mit Jetlag im Gepäck und einem Kopf voller klarer Gedanken über seinen Sport. "Struffi" redet offen darüber, was es bedeutet, als Tennisprofi sein eigenes Unternehmen zu sein – ohne Grundgehalt, mit fixen Kosten für Trainer und Physio, und dem permanenten Druck, performen zu müssen.Wir sprechen über die Dominanz von Alcaraz und Sinner, darüber, wie man als ATP-Spieler seinen Kalender plant, wenn man nicht zu den Top 5 gehört, und was die Einsamkeit im Einzel mit einem macht.Zehn Jahre in den Top 100, ein Titel in München 2024, Matches gegen die Besten der Welt – und trotzdem: Struffi ist einer, der seinen Weg reflektiert, ohne sich etwas vorzumachen. Ein Gespräch über Leistung, Loslassen und die ehrliche Frage, ob man seinen Traumjob wirklich genießt.Jan-Lennard StruffInstagramKontaktwww.bta-pod.comMark HartmannFolge uns aufYouTubeInstagramTikTok

Die größte Chance für Organisationen seit Jahrzehnten

Psychologen Thijs Launspach en Lennard Toma zijn in Zwitserland op een pelgrimstocht langs het leven van een van de belangrijkste en grote denkers binnen de psychiatrie, psychologie en ook wel filosofie van de vorige eeuw, Carl Gustav Jung. Een grote inspiratiebron voor veel mensen, en ook voor Thijs en Lennard. De Zwitserse Jung leefde en werkte vrijwel zijn hele leven daar. Thijs en Lennard bespreken in deze aflevering zijn levensloop, nadat ze bij zijn geboortehuis, woonhuis, zelfgemaakte man-cave kasteel, werkplekken en graf zijn geweest. In de aflevering hierna alles over de belangrijkste ideeën van Jung.

In this week's episode we return to the New Hospital Programme - still one of the most ambitious public infrastructure programmes the UK has seen in decades. The last time I was in NHP's Waterloo office in London was for episode 143 just before Christmas. Then I spoke to Emily King and Doug Baldock about the scale and urgency of the challenge to replace ageing and unsafe hospital infrastructure, and the shift towards industrialised construction through the £37bn Hospital 2.0 programme.Today, we're going deeper into the “how”. Because £37 billion of ambition only becomes reality if the market can actually deliver it.To do that I am joined by Emma Whigham, Alliance Director for the NHP Alliance, and Rick Lennard, Chief Operating Officer for the New Hospital Programme. Together, they're at the sharp end of designing and procuring the Hospital 2.0 Alliance - the new commercial and delivery model intended to underpin the programme for the next 12 years.This is about more than building hospitals. It's about reshaping how the NHS works with industry, creating a stable pipeline that gives suppliers the confidence to invest in skills, manufacturing capacity and modern methods of construction. It's about standardisation without stifling innovation. And it's about learning from decades of fragmented delivery to create something more programmatic, predictable and collaborative.So let's crack on and explore how the Alliance is structured, what early market engagement has changed, where the market pushback really is - or is likely to be. ResourcesNew Hospital Programme: Plan for ImplementationGovernment hospital investment press release Hospital 2.0 AllianceSupplier Guide.Egan review 1998Latham review 1994

Joining me on The Debra Shepherd Podcast today is Ali Lennard who is the Owner and Designer at Philosophy Australia. Philosophy Australia is a Sydney-based womenswear label known for its timeless, versatile garments and commitment to ethical, local production. With several decades in commercial fashion design, Ali's experience and easy-going personality are reflected in her designs.  Philosophy Australia is a multi-award-winning brand with a loyal and growing community of discerning customers who "choose better" and appreciate slow fashion.  In this episode, Ali shares her business story. She talks about purpose, her biggest lessons in business, slow fashion, and what it takes to build a strong brand with staying power and the power of community.  HIGHLIGHTS Ali's path to fashion started at the age of five when she told her kindergarten teacher, she wanted to be in the fashion industry when she grew up.    The growth of Philosophy Australia as a slow fashion brand that is 100% Australian.   The importance of slow fashion, local manufacture and being able to follow garments from start to finish, which Ali says not many companies can do today.  It takes a village and a community to build a business. Ali talks about the power of connection, community and the Philosophy Australia family.   Navigating challenging times in business, the importance of being flexible, and how everything is pivotable.  Staying true to your values and what it takes to build a strong brand with staying power. Ali's talks about meaningful living and what it looks like for her.  Plus, more!   SHOW NOTES Get all episode show notes here:   www.debrashepherd.com.au/debra-shepherd-podcast     CONNECT WITH ALI LENNARD www.philosophyaustralia.com.au Instagram @_PhilosophyAustraliaFashion   CONNECT WITH DEBRA www.debrashepherd.com.au Instagram @_DebraShepherd   Work With Debra

Der russische Angriffskrieg gegen die Ukraine sorgt nicht nur für menschliches Leid. Er verursacht auch erhebliche Umwelt- und Klimaschäden. Der Klimaexperte und Autor einer umfassenden Studie zu dem Thema, Lennard de Klerk, spricht mit Host Stefan Niemann über den CO2-Austoß des Krieges. Der betrage 237 Millionen Tonnen – nach den ersten drei Kriegsjahren. Am meisten Treibhausgase entstünden durch den Treibstoffverbrauch des Militärs. Dazu kommen Emissionen, die durch brennende Wälder, beschädigte Energie-Infrastruktur und umgeleitete Flüge verursacht werden. Der Niederländer de Klerk erläutert darüber hinaus, welche Klimaschäden in Friedenszeiten entstehen, zum Beispiel durch Manöver. Schätzungen zufolge sei das Militär für 5,5 Prozent des weltweiten CO2 Ausstoßes verantwortlich, so der Experte. In der Ukraine geht die systematische Zerstörung der Energieversorgung durch Russlands Terror- und Zermürbungstaktik weiter. Mitten in einem Selenskij-Interview gingen in Kyjiw die Lichter aus. Schwierig bleibt die Lage auch an der Front, vor allen in der heftig umkämpften Stadt Pokrowsk, wie Kai Küstner erklärt. Die ukrainische Führung habe die existenzielle Entscheidung zu fällen, wann der richtige Zeitpunkt zum Rückzug sei, um eine Einkesselung zu vermeiden. Kaum jemand zweifelt daran, dass Pokrowsk fällt, die Frage ist nur wann und wie. Gleichzeitig hat Präsident Selenskyj mit innenpolitischen Problemen zu kämpfen. Ein Korruptionsskandal im Energiesektor erschüttert das Land. Kai berichtet auch über neue Drohnen-Sichtungen – diesmal in Belgien – und den aktuellen Stand in Sachen neuer Wehrdienst. In dieser Woche wollen die Koalitionsfraktionen eine Einigung erzielen. Lob und Kritik, alles bitte per Mail an streitkraefte@ndr.de Strategische Bedeutung von Pokrowsk: https://www.tagesschau.de/ausland/europa/ukraine-krieg-russland-pokrowsk-100.html Anhörung zum neuen Wehrdienst im Bundestag: https://www.youtube.com/watch?v=JPolLmpT2r8 Das Interview mit Lennard de Klerk: https://www.ndr.de/nachrichten/info/audio-326930.html Alle Folgen von “Streitkräfte und Strategien”: https://www.ndr.de/nachrichten/info/podcast2998.html Podcast-Tipp: Weltspiegel Podcast: COP30: Ist der Amazonas-Regenwald noch zu retten? https://www.ardaudiothek.de/episode/urn:ard:episode:689ec368d5da3cfa/

Opeens lijkt hij weer terug van weggeweest. Oud-premier van het Verenigd Koninkrijk, Teflon Tony, Tony Blur, de Poedel van George Bush. Maar u kunt hem kennen als Tony Blair. Waarom is hij terug? Deze week  zijn de zogenoemde vredesonderhandelingen gestart, naar aanleiding van een plan van Trump. Onderdeel van dat vredesplan is het instellen van een bestuur in Gaza, de zogenaamde Vredesraad. Die raad zou moeten bestaan uit internationale toezichthouders. En daarin ligt een speciale rol voor... Tony Blair. Te gast: Verenigd Koninkrijk-kenner Lennard van Otterloo *rectificatie: Macron support wel degelijk het plan van Trump

9/24/25: N'ton City Council Pres Alex Jarrett: municipal health -- money, schools & priorities. CDH Dr “Sunny” Shukla: yr health & weight management. GCC science prof Brian Adams w/ Tom Ricardi on rehabbing raptors. David Boles & Stacey Lennard: our rivers' health & Saturday's Source to Sea Cleanup.

After the fatal shooting of right-wing personality Charlie Kirk on Wednesday afternoon, the rhetoric on the right quickly escalated. Influential voices on social media declared war on the left, despite the absence of any knowledge about the suspect or their motive at the time. President Donald Trump made a formal address where he pledged to go after the “radical left.” “We are seeing language weaponized so swiftly,” says Intercept columnist Natasha Lennard. “I think the Trump administration has a clear track record at this point of taking these little chips that they can leverage to induce state repression and encroach on civil liberties,” says Ali Breland, a staff writer at The Atlantic.This week on The Intercept Briefing, host Akela Lacy speaks to Lennard and Breland about the implications of Kirk's killing and how we think about political violence in the U.S. “We already know that whoever it does turn out to be, we are living in a moment with an authoritarian government that will weaponize this moment either way,” says Lennard. “This is about finding any opportunity to further escalate the white nationalist project.”“I worry that his assassination is a progression toward something darker in which a wider group of people are considered to be targets for political violence,” says Breland. “And I don't think that the rhetoric that's coming out right now is doing anything to stop it or off-ramp us on this dark path.”Listen to the full conversation of The Intercept Briefing on Apple Podcasts, Spotify, or wherever you listen. You can support our work at theintercept.com/join. Your donation, no matter the amount, makes a real difference. Hosted on Acast. See acast.com/privacy for more information.

We talk with Lennard Kooy, CEO of Lleverage, about why nobody actually cares about AI—they care about outcomes. Lennard drops hard truths on why most companies are moving too slow, how to accelerate adoption by assisting before replacing, and where agentic workflows are creating real ROI. He also demos a live “gladiator challenge” of building a cold outreach AI agent from scratch, and outlines what every GTM leader needs to do right now to stay relevant. Whether you're a RevOps pro, a BDR sick of cold calls, or a CMO trying not to get fired—this is your wake-up call.   04:43 Interview with Lennard Kooy 09:36 AI-Powered Recruitment and Sales Automation 14:29 Adopting AI in Business Processes 21:29 Practical AI Workflow Demonstration 23:40 Generating Company Lists and Lead Data 24:24 Simplifying Automation for Users 24:47 User Experience and Customer Support 25:39 Quick Wins for New Users 28:10 Potential of Agentic AI in Go-to-Market 30:59 Guardrails for Adopting AI 32:32 The Power of MCP in AI Integration 35:25 Mid-Market Focus and ROI 37:34 Future of AI in Professional Roles 39:41 Advice for Go-to-Market Leaders 42:29 Quick Hits: Practical AI Tips 44:57 Final Thoughts and Takeaways Key Topics Reality Check: Why most businesses don't care about AI—and what they do care about The Trust Layer: How “assist before replace” is the cheat code for adoption Recruiting Reinvented: How Lleverage AI automated 70% of their hiring pipeline Agentic GTM: Where agent workflows are replacing cold calls, research, and lead scoring Demo Time: Watch Lennard build an AI agent live, in under 5 minutes MCP Advantage: Why this new spec removes dev bottlenecks and boosts AI usability Speed > Perfection: Why going slow will kill your competitive edge Hard Truths for Leaders: You will get replaced if you don't move faster Future of Work: What GTM roles look like in a near-agentic future About our Guest: Lennard Kooy is a seasoned tech entrepreneur focused on how emerging technologies can transform business operations. As CEO of AI platform Lleverage, he helps companies automate complex processes without requiring technical expertise, drawing from his experience building and selling martech company Storyteq to ITG. Known for his pragmatic approach to AI adoption, Lennard regularly shares insights on making advanced automation accessible to everyday business teams. He's passionate about strengthening Europe's position in the global AI landscape and frequently writes about the practical realities of implementing AI in enterprise settings.

In this episode, we talk with Jai Lennard about opportunity versus access. Jai discusses how part of his ethical considerations include deciding if he is the right person to tell a story. Additionally, his founding of Color Positive was part of his drive to diversify the stories which are told by aiding young black artists. Jai outlines how his mentoring role at Color Positive puts him in a place of access to talent enabling him to connect photographers with projects that they are aligned with. Access is also explored in relation to opportunity as Jai discusses how both are needed for artists to succeed.What you'll find inside: “I think that a lot of the subjects that I used to be more head on with dealing with actual people, dealing with survivors, dealing with people who are on the ground trying to change the world. Those same stories get told in entertainment… everyone wants to tell stories different ways.” (7.08)“If I'm being approached about a project, is this a topic that I want to dive into? Should I be telling this story?... It's always case by case for me, I take everything individually I don't really have blanket answers.” (8.12)“I just kind of always knew I needed a mentor and I think maybe that's also back to just my background. Growing up as a young black man in a mostly white community – despite how diverse my area was – I just always knew that if I was going to succeed, I wasn't going to do it on my own.” (18.52)“You can be asked to do a job that sounds amazing and when you get there, you have not been set up to succeed and that is the difference between having access and not having access…there's so many different kinds of access, an opportunity is just an opportunity and without access it's not a lot.” (36.23)What does photography ethics mean to Jai? “Putting the wellbeing of everyone who's involved at the forefront of your mind when you do a project. When it's there you're protective of it and I think that photography ethics is about being protective to what's important on every scenario. And it may seem like a lot times the most important thing is just to get it but it's usually not. For me, a lot of the times it's about the experience. When I focus on the experience as the most important thing for a photography project a lot of other things come into play very smoothly including the images.” (39.25)Links:Color PositiveWomen PhotographColor Positive MentorshipDanielle Villasana: On representation and eq

Willkommen zu einer neuen Ausgabe von Chip & Charge - heute mit der vierten Tageszusammenfassung aus Wimbledon. Philipp ist nicht verfügbar, deswegen hat sich Andreas wieder Lukas Zahrer vom Standard eingeladen. Die beiden sprechen über die acht Matches der dritten Runde bei Damen und Herren. Laura Siegemund schrieb dabei aus deutscher Sicht die beste Geschichte. Sie besiegte Madison Keys überraschend klar in zwei Sätzen und steht erstmals in ihrer Karriere im Achtelfinale in Wimbledon. Mit 37 Jahren und dem eigentlichen Fokus aufs Doppel haut sie auch immer wieder großartige Einzelergebnisse raus. Aryna Sabalenka musste am Abend hart arbeiten, um Emma Raducanu in ... WERBUNG 10 Euro gratis bei NEO.bet Sichert euch 10 Euro gratis beim Wettanbieter NEObet, ganz ohne Einzahlung. Einfach den Promotion-Code tennis10 bei der Registrierung auf neobet.de eingeben und sofort mit den 10 Euro loswetten. Link zur NEObet-Registrierung: https://neobet.de/de/Sportwetten#account/Account Dieser Podcast wird vermarktet von der Podcastbude.www.podcastbu.de - Full-Service-Podcast-Agentur - Konzeption, Produktion, Vermarktung, Distribution und Hosting.Du möchtest deinen Podcast auch kostenlos hosten und damit Geld verdienen?Dann schaue auf www.kostenlos-hosten.de und informiere dich.Dort erhältst du alle Informationen zu unseren kostenlosen Podcast-Hosting-Angeboten. kostenlos-hosten.de ist ein Produkt der Podcastbude.Führung beginnt mit Gefühl: Im Podcast Führungsgefühle erfährst du, wie emotionale Intelligenz, Selbstreflexion und neue Leadership-Ansätze echte Veränderung bewirken können. Jetzt entdecken auf www.fuehrungsgefuehle.de.

Was bleibt, wenn sich alles verändert? In dieser Folge von From Done To spricht Arne mit Lars Lennard Geiswald – Autor, Podcaster und praktizierender Stoiker – über den über 2000 Jahre alten Weg des Stoizismus. Gemeinsam tauchen sie tief in Themen wie innere Ruhe, Identität, Mut, Veränderung und bewusste Lebensführung ein. Warum stoische Philosophie heute aktueller denn je ist, wie man mit Krisen und Selbstzweifeln umgeht und was es heißt, ein gutes Leben zu führen – das alles erfährst du in diesem ehrlichen, tiefgründigen und inspirierenden Gespräch.

On Energy Evolution this week, Eklavya Gupte and Rosemary Griffin examine the often-overlooked environmental ramifications of military conflicts as we mark the third anniversary of the Russia-Ukraine war. Lennard de Klerk, who has studied the climate impact of this war, gives us some insights into how warfare, fuel consumption, forest fires, attacks on energy infrastructure and the estimated costs of rebuilding Ukraine have led to a surge in greenhouse gas emissions. As concerns around the climate costs of war have intensified, there have been wider calls for military emissions to be calculated and included in international reporting. We speak to Patrick Bigger, research director at the Climate and Community Institute, and Benjamin Neimark, a senior lecturer at the School of Business and Management at Queen Mary University of London, to learn more about the growing carbon footprint of militaries globally. Energy Evolution has merged with Platts Future Energy, and episodes are now published on Tuesdays.

Today, we're thrilled to welcome Donna Lennard, a trailblazer who has redefined how we experience dining, design, and community.Donna is the founder of the iconic il Buco family of restaurants—destinations renowned for their ingredient-driven Italian and Mediterranean cuisine—and il Buco Vita, a lifestyle and tabletop brand rooted in craftsmanship and cultural heritage. What began as an unassuming antique shop on Bond Street has, over the last three decades, blossomed into a beloved collection of spaces that feel more like homes than restaurants.From her beginnings working in the kitchen to her journey into antiques and culinary artistry, Donna has built a world where every detail—from the handmade dishes to the plate it's served on—tells a story. Her ability to bridge the worlds of collecting and curating, in both food and design, creates an atmosphere of warmth, connection, and timeless elegance.Donna shares how it all started, the pivotal moments that shaped il Buco's evolution, and the parallels between curating antiques and crafting unforgettable dining experiences. We'll also explore the balance between consistency and evolution, the importance of community, and the future of il Buco's ever-growing world. So with great honor, this is Donna Lennard, for Collectors Gene Radio.il Buco - https://ilbuco.com/Collectors Gene - https://collectorsgene.com/il Buco's Instagram - https://www.instagram.com/ilbuconycCameron's Instagram - https://www.instagram.com/cameronrosssteiner

For generations most of the canonical works that detail the lives of poor people have been created by rich or middle-class writers like Charles Dickens, John Steinbeck, or James Agee. This has resulted in overwhelming depictions of poor people as living abject, violent lives in filthy and degrading conditions.  In Poor Things: How Those with Money Depict Those Without It (Duke UP, 2024), Lennard J. Davis labels this genre ‘poornography”: distorted narratives of poverty written by and for the middle and upper classes. Davis shows how poornography creates harmful and dangerous stereotypes that build barriers to social justice and change. To remedy this, Davis argues, poor people should write realistic depictions of themselves, but because of representational inequality they cannot. Given the obstacles to the poor accessing the means of publication, Davis suggests that the work should, at least for now, be done by “transclass” writers who were once poor and who can accurately represent poverty without relying on stereotypes and clichés. Only then can the lived experience of poverty be more fully realized. The Endo/Exo Writers Project. Nathan Smith is a PhD candidate in Music Theory at Yale University nathan.smith@yale.edu Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

For generations most of the canonical works that detail the lives of poor people have been created by rich or middle-class writers like Charles Dickens, John Steinbeck, or James Agee. This has resulted in overwhelming depictions of poor people as living abject, violent lives in filthy and degrading conditions.  In Poor Things: How Those with Money Depict Those Without It (Duke UP, 2024), Lennard J. Davis labels this genre ‘poornography”: distorted narratives of poverty written by and for the middle and upper classes. Davis shows how poornography creates harmful and dangerous stereotypes that build barriers to social justice and change. To remedy this, Davis argues, poor people should write realistic depictions of themselves, but because of representational inequality they cannot. Given the obstacles to the poor accessing the means of publication, Davis suggests that the work should, at least for now, be done by “transclass” writers who were once poor and who can accurately represent poverty without relying on stereotypes and clichés. Only then can the lived experience of poverty be more fully realized. The Endo/Exo Writers Project. Nathan Smith is a PhD candidate in Music Theory at Yale University nathan.smith@yale.edu Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/literary-studies

Originally aired November 15, 2024 In the wake of President-elect Donald Trump's victory, Democrats and those on the left are grappling with what comes next.On The Intercept Briefing podcast this week, columnist Natasha Lennard critiques the Democratic Party. “You can't be both at once: You can't be the party of Wall Street, and you can't be the party of the working class,” Lennard says. By acquiescing to Silicon Valley and Wall Street, the Democrats failed again “to offer a robust politics that serves the working class."Facing a second Trump term, Lennard says the way forward is a politics of everyday life and radical action that focuses on empowering grassroots movements and labor organizations. “When we look at what people can [do] — involving people at a local level, building community so that it is truly kind of a form of life to be in this politics, rather than just a donation, rather than just a vote, rather than just canvassing even.”In conversation with Jessica Washington and Jordan Uhl, Lennard emphasizes the importance and resilience of the working class. "Nurses unions, food workers unions. Most of the working class in this country are women. And it is a profoundly multi-racial working class. And we have a working class of care workers. And a service economy. And an increasingly growing care economy," she says. "That needs investing in. That needs support. That needs building."To hear more about the future of progressive politics, listen to this week's episode of The Intercept Briefing.If you want to support our work, you can go to theintercept.com/join. Your donation, no matter what the amount, makes a real difference. If you haven't already, please subscribe to The Intercept, wherever you listen to podcasts. And definitely leave us a rating or a review, it helps other listeners to find us. Hosted on Acast. See acast.com/privacy for more information.

In the wake of President-elect Donald Trump's victory, Democrats and those on the left are grappling with what comes next.On The Intercept Briefing podcast this week, columnist Natasha Lennard critiques the Democratic Party. “You can't be both at once: You can't be the party of Wall Street, and you can't be the party of the working class,” Lennard says. By acquiescing to Silicon Valley and Wall Street, the Democrats failed again “to offer a robust politics that serves the working class."Facing a second Trump term, Lennard says the way forward is a politics of everyday life and radical action that focuses on empowering grassroots movements and labor organizations. “When we look at what people can [do] — involving people at a local level, building community so that it is truly kind of a form of life to be in this politics, rather than just a donation, rather than just a vote, rather than just canvassing even.”In conversation with Jessica Washington and Jordan Uhl, Lennard emphasizes the importance and resilience of the working class. "Nurses unions, food workers unions. Most of the working class in this country are women. And it is a profoundly multi-racial working class. And we have a working class of care workers. And a service economy. And an increasingly growing care economy," she says. "That needs investing in. That needs support. That needs building."To hear more about the future of progressive politics, listen to this week's episode of The Intercept Briefing. Hosted on Acast. See acast.com/privacy for more information.

Lennard Zinn is a bike designer and frame builder based in Louisville, Colorado. His shop, Zinn Cycles, offers "a full line of semi-custom and off the shelf bikes for riders from very small to very tall and everyone in-between." He's also the author of Zinn and the Art of Mountain Bike Maintenance, one of the world's best-selling guides to mountain bike repair. In this first-half of our podcast discussion, Zinn talks about drivetrain maintenance, focusing on chains and lubrication. Later in the show we talk about the benefits of big 32-, 36-inch, and 750d bike wheels and designing bikes for riders both tall and small. Understanding bike chain wear and elongation 0:00 Chain wear is caused by dirt and oil-based lubricant sticking to the chain, creating a grinding paste that wears down the rollers, bushings, and pins. Zinn describes how the chain's inner links are made. The chain's flexibility increases as the bushings and plates wear, affecting shifting performance. A chain's lateral stiffness is crucial for proper shifting, and a worn chain can cause skipping during shifting. Chain elongation and its effects 6:46 Zinn discusses how a chain's elongation affects its performance, particularly when the distance between rollers exceeds the half-inch standard. He explains that a worn chain can misshape the cassette's teeth, leading to skipping and poor shifting. Chain checkers can be used to ensure the chain's length is within spec to prevent cassette wear. Lubrication and its impact on chain wear 22:35 Zinn explains that a dry chain will wear faster due to friction, while lubrication helps reduce wear but can attract dirt. He discusses the differences between factory lube and other lubricants, noting that factory lube is designed for machinery, not for low friction on the bike. Zinn recommends using a cleaner to remove factory lube before applying chain lube. He introduces the concept of chain waxing, which involves immersing the chain in molten wax to create a low-friction, clean-running chain. Zinn shares the benefits of chain waxing, including reduced noise, lower friction, and longer chain life. Chain waxing process and benefits 35:43 Zinn describes the process of chain waxing, including the need for a clean jar of mineral spirits and denatured alcohol for cleaning the chain. He mentions the cost-effectiveness of chain waxing compared to replacing chains frequently. Wheel sizes and their applications 1:03:20 Zinn discusses the advantages of larger wheels for tall riders like 32-, 36-inch, and 750d wheels, noting that 32-inch wheels can make a bike look proportionally sized. He explains the challenges of using larger wheels, such as increased weight and the lack of suspension forks. Zinn mentions the development of new carbon rims and tires for larger wheels, which could improve their performance and weight. Barber asks about the feasibility of using suspension forks with larger wheels, and Zinn confirms that rigid forks are the only option. Challenges in designing bikes for small riders 1:16:58 Barber asks about the challenges of scaling bikes for smaller riders, and Zinn explains the limitations due to the need for certain components. Zinn highlights the importance of proportional design, where larger wheels can make a bike look more proportionate for tall riders. He discusses the ergonomic issues for small riders, such as wider Q-factors and shorter steerer tubes on forks. Zinn mentions the UCI's weight limit in road racing as an example of how smaller riders are often disadvantaged. Modern trends in bike design and their impact 1:18:46 Zinn highlights the shortening of steerer tubes on forks which can be a problem for taller riders. He discusses the trend of wider rear ends in modern bikes, which can be detrimental to smaller riders due to increased Q-factor. Find out more about the chain waxing service and bikes discussed in this episode at zinncycles.com. --- Support this podcast: https://podcasters.spotify.com/pod/show/singletracks/support

Within the first 100 days of its war on Gaza, the Israeli military systematically destroyed every single university on the strip. International human rights monitors have found significant evidence that Palestinian scholars and intellectual figures have been targeted by Israeli strikes. The Israeli military has decimated Gaza's education system and its infrastructure. This week on Deconstructed, Natasha Lennard, a columnist for The Intercept, fills in for Ryan Grim and speaks with Dr. Ahmed Alhussaina, the vice president of Israa University, one of Gaza's most celebrated institutions of higher education and research. At the start of the war, Israel turned the university into military barracks, and later destroyed it in a massive, controlled explosion. In mid-November, Alhussaina fled Gaza; he has been able to escape to Egypt with his direct family members. Israel's current war has killed 102 of his relatives. Alhussaina told Lennard about academic life in Gaza before October 7, the unending terror and desperation for Palestinians since the war began, and his hopes for the future of Palestinian intellectual life.If you'd like to support our work, go to theintercept.com/give, where your donation, no matter what the amount, makes a real difference.And if you haven't already, please subscribe to the show so you can hear it every week. And please go and leave us a rating or a review — it helps people find the show. If you want to give us additional feedback, email us at Podcasts@theintercept.com. Hosted on Acast. See acast.com/privacy for more information.